Comment
Author: Admin | 2025-04-28
By 7 cents. Revenues dropped 4.8% YoY to $3.75 billion, handily beating consensus estimates for $3.72 billion. Its portfolio of legacy blockbuster drugs continues to decline in revenue as expected, but its new drugs are growing in Emerging Markets, Europe, and China. Generics saw divestiture-adjusted growth of 4% versus 2% YoY growth in Branded drugs. Viatris has been paying down its debt from $17 billion at the start of 2024 to a projected $14 billion by the end of the year. The company plans to return 50% of the free cash flow to shareholders and apply 50% for stock buyback upon achieving a 2.8x to 3.2x EBITDA range.The company will be releasing EFFEXOR for anxiety and INPEFA for heart failure, which are highly anticipated growth drivers. The new products revenue forecast was raised from $500 million to $600 million by year's end. Shares surged 13% the following day after its earnings release. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Add Comment